CNS Pharmaceuticals Stock Price, News & Analysis

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) announced that CEO John Climaco will present at the Emerging Growth Virtual Conference on March 17-18, 2021. The event will feature discussions on glioblastoma, with Climaco participating in a panel on March 17 from 9:30-10:30 am ET. CNS is focused on developing treatments for brain and central nervous system cancers, including their lead drug candidate, Berubicin, aimed at glioblastoma multiforme. CNS plans to initiate a Phase 2 trial for Berubicin in the U.S. in 2021.

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) announced that CEO John Climaco will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The company specializes in developing treatments for brain cancers. Participants can join virtual one-on-one meetings with management and view a video webcast of the presentation starting March 9 at 7:00 AM ET. CNS's lead drug candidate, Berubicin, targets glioblastoma multiforme and has shown a 44% response rate in previous trials. A Phase 2 trial is expected in 2021.

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) announced that its clinical program for Berubicin, a novel treatment targeting glioblastoma multiforme (GBM), is set to start enrolling patients in March 2021. Berubicin is the first anthracycline capable of crossing the blood-brain barrier, aiming to improve outcomes for patients with this aggressive cancer. The study will involve approximately 35 clinical sites, with 21 currently confirmed. The primary endpoint is Overall Survival, with results expected to offer vital data for FDA approval. The FDA has granted Orphan Drug designation for Berubicin, ensuring marketing exclusivity.

On February 18, 2021, CNS Pharmaceuticals (NASDAQ: CNSP) announced that WPD Pharmaceuticals received a positive opinion from the Lower Silesian Medical Chamber Ethics Committee for its Berubicin clinical trial targeting Glioblastoma Multiforme (GBM). CNS also obtained Central IRB approval for its CNS-201 trial, marking a significant step in the collaborative development of Berubicin. The U.S. FDA has approved CNS's Investigational New Drug application for Berubicin, with a Phase 2 trial set to commence in Q1 2021. WPD plans to initiate multiple trials in 2021, supported by a $6 million grant.

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) announced that CEO John Climaco will present at the H.C. Wainwright BioConnect 2021 Conference from January 11-14, 2021. The presentation is scheduled for January 11 at 6:00 AM ET, with a webcast available on demand afterward. CNS Pharmaceuticals focuses on innovative treatments for brain and central nervous system cancers, particularly its lead drug candidate, Berubicin, which targets glioblastoma multiforme. A Phase 2 trial for Berubicin is expected to begin in the U.S. by the end of Q1 2021.

CNS Pharmaceuticals, a biopharmaceutical firm, announced FDA approval for its Investigational New Drug application for Berubicin, aimed at treating Glioblastoma Multiforme (GBM). This marks a significant step in CNS's mission to address the unmet medical needs for GBM, a highly aggressive cancer. The company plans to initiate a Phase 2 clinical trial in the U.S. in early 2021, alongside trials by its sublicensee in Poland. Promising Phase 1 results demonstrated a 44% disease control rate, supporting Berubicin's potential in improving patient outcomes.

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) announced a public offering of 5 million shares of common stock at $2.00 each, alongside warrants to purchase 2.5 million shares at an exercise price of $2.20. The offering is expected to close around December 28, 2020. Proceeds will fund a Phase 2 trial for Berubicin, a potential treatment for aggressive brain cancer, and support further R&D and working capital. The underwriter has a 45-day option to purchase additional shares and warrants for over-allotments. The offering follows an effective registration statement filed with the SEC.

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) has announced a conference call and live webcast on December 18, 2020, at 8:30 AM ET to discuss its IND approval for Berubicin, aimed at treating Glioblastoma Multiforme (GBM). The planned Phase 2 clinical trial will begin by Q1 2021 in the U.S., with additional trials in Poland for pediatric patients. CNS holds exclusive rights to Berubicin, previously showing a 44% disease control rate in an earlier Phase 1 trial. Details for accessing the call and its replay are provided in the announcement.

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) announced the FDA approval of its Investigational New Drug (IND) application for Berubicin, intended for treating Glioblastoma Multiforme (GBM). The Phase 2 clinical trial is set to commence in Q1 2021, targeting adults who have not responded to first-line treatments. The trial will focus on overall survival as the primary endpoint, comparing Berubicin against Lomustine. CNSP aims to address the critical unmet medical needs in GBM treatment, building on promising Phase 1 results where a 44% disease control rate was achieved.